While maintenance immunosuppression is used to inhibit the proliferation of T cells following induction therapy, none of the therapies currently on the market target the IL-7 axis, despite its known role in the homeostatic expansion of T cells during lymphopenia. The gene discussed is IL7; the disease is lymphopenia.